AVEO Pharmaceuticals, Inc. (AVEO)

[n3m3sis]

Remember there are more Catalysts to come.

The EC, which typically adheres to the recommendation of the CHMP, but is not obligated to do so, is expected to make its final decision in about 67 days. If approved by the EC, marketing authorization for tivozanib will be granted in all 28 countries of the European Union, Norway, Iceland and Liechtenstein. EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, is the European licensee for tivozanib.

source

Also, if approved for marketing by the EC commission, it will put
pressure on the FDA.

The short squeeze is well and truly on!

GO $AVEO